Clinical collaborations help cancer immunotherapy research move from laboratory work to coordinated trials and regulatory review by connecting cancer centers, researchers, government agencies, drug developers, and patient-outcomes experts. They provide trial infrastructure, investigational agents, scientific expertise, and ways to assess patients’ experiences. These mechanisms support evidence generation; the institutional sources below do not show that collaboration itself causes better immunotherapy response, survival, or quality of life.
How collaboration supports the path from research to trials
Immunotherapy research can involve several stages: laboratory investigation, early human studies, larger clinical trials, and regulatory assessment. Different partnerships address different needs along that path. Some coordinate sites and trial operations; others make investigational agents available, pool expertise, or develop methods for evaluating treatment effects.
As an Amazon Associate I earn from qualifying purchases.
The National Cancer Institute (NCI) supports cancer-research infrastructure, including the National Clinical Trials Network (NCTN), which supports trials at thousands of sites in the United States, Canada, and internationally. The NCTN is a broad cancer-trial network—not every participating site is conducting an immunotherapy study. NCI’s overview of cancer research infrastructure describes this network and related resources.
Recommended Free Tools
NCI-designated cancer centers contribute laboratory, clinical, and translational research, and their studies may involve other centers, industry, or community partners. NCI reports that approximately 400,000 patients receive cancer diagnoses at these centers each year; that figure, on a page updated May 20, 2026, concerns diagnoses, not immunotherapy-trial enrollment. NCI’s cancer-center overview describes the centers and their research role.
#1 Best Overall
What different partnerships contribute
| Collaboration model | Who is involved | What it contributes | What it does not establish |
|---|---|---|---|
| Trial networks and cancer centers | NCI, cancer centers, researchers, and participating trial sites | Infrastructure and coordination for studies across multiple locations | That every site runs immunotherapy trials, or that the network itself improves treatment outcomes |
| Cooperative research agreements | NCI researchers and private-sector partner scientists | Shared work that can include laboratory and early human studies of technologies or therapies | That a candidate treatment will succeed in later trials |
| NCI Formulary | NCI and participating pharmaceutical or biotechnology companies | Access to investigational agents for approved cancer-trial proposals, including studies of molecular pathways | General patient access to drugs or a guarantee of trial eligibility |
| Regulatory-science programs | FDA experts across centers and external collaborators | Research and expertise for evaluating safety and effectiveness, including approaches to combination regimens | An FDA endorsement or proof of benefit for a particular therapy |
| Patient-outcomes work | FDA, external stakeholders, patients, and research partners | Methods for capturing symptoms, side effects, function, and quality of life alongside clinical measures | A substitute for tumor, survival, or other clinical evidence |
How NCI and industry share research work and trial agents
Cooperative research agreements
NCI describes Cooperative Research and Development Agreements (CRADAs) as a way for NCI researchers and private-sector scientists to work together. The agency says CRADAs are increasingly used in developing targeted therapies and immunotherapy treatments. These partnerships can support laboratory and early human studies that move promising technologies or therapies toward later-stage studies; they do not guarantee that a therapy will prove safe or effective. NCI also describes precision-medicine trials such as MATCH, which use FDA-approved and investigational therapies from multiple companies. See NCI’s Technology Transfer and Small Business Partnerships page.
The NCI Formulary
The NCI Formulary is a public-private partnership through which pharmaceutical and biotechnology companies provide agents for cancer clinical trials. For studies focused on molecular pathways, it can make it easier to obtain agents from multiple companies. Company collaborators review proposals and provide agents for approved studies, so this is a research mechanism—not a route for patients to obtain investigational drugs outside an authorized study. Proposal requirements apply, and participating companies or available agents may change. Details are on NCI’s Formulary page.
Rank #2
How FDA collaboration informs immunotherapy evaluation
Immuno-Oncology Therapeutics Program
FDA’s Immuno-Oncology Therapeutics Program brings expertise together across FDA centers and supports education, regulatory-science research, and improved clinical-trial approaches for evaluating safety and effectiveness. Its work includes trial paradigms for combination regimens. This is activity aimed at strengthening evaluation, not a blanket endorsement of combination therapy or evidence that a specific regimen benefits patients. The program’s scope is described on FDA’s Immuno-Oncology page.
Oncology Center of Excellence
FDA’s Oncology Center of Excellence (OCE) coordinates oncology expertise and lists work involving international review, trial design, research collaboration, and access. Its stated mission is “to achieve patient-centered regulatory decision-making through innovation and collaboration.” Regulatory collaboration differs from a research partnership that tests a treatment: it concerns how evidence is generated, assessed, and used in decisions. Read more on FDA’s OCE page.
FDA–NCI research collaboration
One example of agency collaboration is the FDA–NCI memorandum of understanding on clinical proteogenomics cancer research. The agreement sets out a collaboration’s scope; it should not be read as evidence of clinical benefit from an immunotherapy. The amendment took effect August 24, 2022. The document is available at FDA’s MOU 225-17-014 page.
Why patient-reported outcomes matter
Tumor measurements and survival data are central to evaluating cancer therapies, but they do not capture every effect a patient experiences. FDA’s patient-focused drug development work involves external stakeholders and supports methods for assessing symptoms, side effects, physical function, and quality of life alongside clinical information. This can help trials collect a fuller account of treatment burden and benefit.
Rank #4
FDA says its Oncology Center of Excellence, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research published 2021 guidance addressing core patient-reported outcomes in cancer trials and trial-design considerations. FDA lists work with academic institutions and NCI among its examples. Patient-reported measures complement rather than replace tumor and survival information. See FDA’s Patient-Focused Drug Development page.
What the evidence does—and does not—show
The institutional descriptions establish that these collaboration models exist and explain their intended functions: coordinating trial infrastructure, enabling access to investigational agents, sharing scientific expertise, improving regulatory-science methods, and incorporating patient-reported outcomes. They do not quantify a causal effect of collaboration itself on immunotherapy efficacy, survival, or quality of life. Those outcomes require evidence from individual trials or evaluations that directly measure them.
The examples are not a complete inventory of cancer immunotherapy partnerships. They illustrate complementary roles, not a ranking of which model is best: the appropriate arrangement depends on the research stage, the partners involved, and what needs to be shared.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
